MF59-Adjuvanted Trivalent Influenza Vaccine Favored Over HD-TIV In High-Risk Older Adults, Research Finds

Infectious Disease Advisor (9/25, Basilio) reports research found that “the MF59-adjuvanted trivalent influenza vaccine (aTIV) has comparable effectiveness to the high-dose trivalent inactivated influenza vaccine (HD-TIV) in older adults with no risk factors.” But, “aTIV is favored over HD-TIV for high-risk older adults.” The findings were published in Open Forum Infectious Diseases.